



T0070907

Catalog No: tcsc0462

Available Sizes
Size: 5mg
Size: 10mg
Size: 50mg
Size: 100mg
Specifications
CAS No: 313516-66-4
Formula: C ₁₂ H ₈ CIN ₃ O ₃
Pathway: Cell Cycle/DNA Damage;Cell Cycle/DNA Damage
Target: PPAR;RAD51
Purity / Grade: >98%
Solubility: DMSO : 10 mg/mL (36.02 mM; Need ultrasonic)
Observed Molecular Weight:

Product Description

277.66

T0070907 is a potent **PPARy** antagonist and a potential **RAD51** inhibitor, with apparent $\mathbf{K_i}$ value of 1 nM towards PPARy.





IC50 & Target: Ki: 1 nM (PPAR γ), 1.8 μ M (PPAR δ), 0.85 μ M (PPAR α)^[4]

In Vitro: T0070907 (50 μM) pre-treatment impairs repair of IR-induced DNA DSBs in both ME-180 and SiHa cells treated with irradiated (4 Gy). T0070907 (0-50 μM) significantly decreases the levels of DNA-PKcs and RAD51 proteins in ME-180 and SiHa cells [1] . T0070907 (50 μM) treatment reduces the levels of α - and β -tubulin protein in a time-dependent manner, decreases the synthesis of DNA, and prevents the radiation-induced alterations in the cell cycle regulatory proteins of ME180 and SiHa cells [2]. T0070907 (10 μM) has cytotoxicity in an adipocyte-specific and PPARγ-independent manner. T0070907 increases oxidative stress in immature adipocytes [3]. T0070907 (1 μM) blocks the induction of adipogenesis by various treatments of the adipogenic cell line 3T3-L1. T0070907 covalently modifies PPAR on cysteine 313 in helix 3 of human PPAR 2 [4].

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!